Physician profile
Matthew Perez
NPI 1578927398
$6,104.77
in general payments reported to CMS, 2019-2025
26 companies · $1,786 in 2025
The $1,786 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $21.63 · 2021: $370 · 2022: $1,102 · 2023: $885 · 2024: $1,663 · 2025: $1,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,218 · Consulting Fee: $61.85 · Education: $53.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,217.51 |
| Consulting Fee | $61.85 |
| Education | $53.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,328.01 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $917.74 | 2021-2025 | |
| Glaxosmithkline, LLC. | $612.66 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $392.92 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $354.67 | 2022-2025 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $353.21 | 2021-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $352.97 | 2023-2025 | Orladeyo |
| Amgen INC. | $347.71 | 2021-2025 | Tezspire, Actimmune |
| Pfizer INC. | $244.03 | 2021-2025 | |
| Alk-Abello, INC | $237.20 | 2019-2024 | Grastek, Ragwitek, Odactra |
| Novartis Pharmaceuticals Corporation | $185.10 | 2022-2025 | |
| Kaleo, INC. | $105.10 | 2021-2024 | Auvi-Q |
| Genentech USA, INC. | $95.70 | 2022-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Grifols USA, LLC | $72.64 | 2022-2025 | Xembify |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $71.58 | 2022-2025 | Andembry, Hizentra |
| Ars Pharmaceuticals Operations, INC. | $67.67 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $61.85 | 2025 | |
| Abbvie INC. | $47.21 | 2022 | |
| Blueprint Medicines Corporation | $46.91 | 2023-2025 | Ayvakit |
| Tersera Therapeutics LLC | $31.93 | 2024 | Quzyttir |
| Pharming Healthcare, INC. | $26.22 | 2024 | Ruconest |
| Lilly USA, LLC | $23.30 | 2025 | Ebglyss |
| Organon LLC | $20.50 | 2025 | Vtama |
| Ionis Pharmaceuticals, INC. | $17.76 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $15.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.